These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
271 related articles for article (PubMed ID: 28749919)
1. Philadelphia chromosome-like acute lymphoblastic leukemia: progress in a new cancer subtype. Wells J; Jain N; Konopleva M Clin Adv Hematol Oncol; 2017 Jul; 15(7):554-561. PubMed ID: 28749919 [TBL] [Abstract][Full Text] [Related]
2. How is the Ph-like signature being incorporated into ALL therapy? Maese L; Tasian SK; Raetz EA Best Pract Res Clin Haematol; 2017 Sep; 30(3):222-228. PubMed ID: 29050695 [TBL] [Abstract][Full Text] [Related]
3. Rapid molecular response to dasatinib in Ph-like acute lymphoblastic leukemia patients with ABL1 rearrangements: case series and literature review. Tan KW; Zhu YY; Qiu QC; Wang M; Shen HJ; Huang SM; Cao HY; Wan CL; Li YY; Dai HP; Xue SL Ann Hematol; 2023 Sep; 102(9):2397-2402. PubMed ID: 37103615 [TBL] [Abstract][Full Text] [Related]
4. Janus kinase inhibition by ruxolitinib extends dasatinib- and dexamethasone-induced remissions in a mouse model of Ph+ ALL. Appelmann I; Rillahan CD; de Stanchina E; Carbonetti G; Chen C; Lowe SW; Sherr CJ Blood; 2015 Feb; 125(9):1444-51. PubMed ID: 25499760 [TBL] [Abstract][Full Text] [Related]
5. Why and how to treat Ph-like ALL? Roberts KG Best Pract Res Clin Haematol; 2018 Dec; 31(4):351-356. PubMed ID: 30466746 [TBL] [Abstract][Full Text] [Related]
6. BCR/ABL1 Kinase Domain Mutation Monitoring: Could Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Benefit As Well? Andolina JR Acta Haematol; 2015; 134(2):69-70. PubMed ID: 25895547 [No Abstract] [Full Text] [Related]
7. The biology of Philadelphia chromosome-like ALL. Roberts KG Best Pract Res Clin Haematol; 2017 Sep; 30(3):212-221. PubMed ID: 29050694 [TBL] [Abstract][Full Text] [Related]
9. Next-generation sequencing for BCR-ABL1 kinase domain mutations in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A position paper. Soverini S; Albano F; Bassan R; Fabbiano F; Ferrara F; Foà R; Olivieri A; Rambaldi A; Rossi G; Sica S; Specchia G; Venditti A; Barosi G; Pane F Cancer Med; 2020 May; 9(9):2960-2970. PubMed ID: 32154668 [TBL] [Abstract][Full Text] [Related]
10. Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL. Rousselot P; Coudé MM; Gokbuget N; Gambacorti Passerini C; Hayette S; Cayuela JM; Huguet F; Leguay T; Chevallier P; Salanoubat C; Bonmati C; Alexis M; Hunault M; Glaisner S; Agape P; Berthou C; Jourdan E; Fernandes J; Sutton L; Banos A; Reman O; Lioure B; Thomas X; Ifrah N; Lafage-Pochitaloff M; Bornand A; Morisset L; Robin V; Pfeifer H; Delannoy A; Ribera J; Bassan R; Delord M; Hoelzer D; Dombret H; Ottmann OG; Blood; 2016 Aug; 128(6):774-82. PubMed ID: 27121472 [TBL] [Abstract][Full Text] [Related]
11. Which tyrosine kinase inhibitor should we use to treat Philadelphia chromosome-positive acute lymphoblastic leukemia? Short NJ; Kantarjian H; Jabbour E; Ravandi F Best Pract Res Clin Haematol; 2017 Sep; 30(3):193-200. PubMed ID: 29050692 [TBL] [Abstract][Full Text] [Related]
12. A case report of a truncated ABL1 mutation in 2 cases with Philadelphia chromosome-positive B cell precursor acute lymphoblastic leukemia. Kato K; Takagi S; Takano H; Tsunoda S; Watanabe O; Yamaguchi K; Kageyama K; Kaji D; Taya Y; Nishida A; Ishiwata K; Yamamoto H; Yamamoto G; Asano-Mori Y; Koike Y; Makino S; Wake A; Taniguchi S; Uchida N Int J Hematol; 2024 Feb; 119(2):205-209. PubMed ID: 38236369 [TBL] [Abstract][Full Text] [Related]
14. Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1 Mian AA; Haberbosch I; Khamaisie H; Agbarya A; Pietsch L; Eshel E; Najib D; Chiriches C; Ottmann OG; Hantschel O; Biondi RM; Ruthardt M; Mahajna J Ann Hematol; 2021 Aug; 100(8):2023-2029. PubMed ID: 34110462 [TBL] [Abstract][Full Text] [Related]
15. From the archives of MD Anderson Cancer Center: Concurrent BCR-ABL1 and CRLF2 rearrangements in B-lymphoblast phase of chronic myeloid leukemia. Thakral B; Jain N; Tang G; Konoplev S; Vega F; Medeiros LJ; Wang SA Ann Diagn Pathol; 2021 Aug; 53():151767. PubMed ID: 34118580 [TBL] [Abstract][Full Text] [Related]
16. Philadelphia Chromosome-like Acute Lymphoblastic Leukemia. Pui CH; Roberts KG; Yang JJ; Mullighan CG Clin Lymphoma Myeloma Leuk; 2017 Aug; 17(8):464-470. PubMed ID: 28842136 [TBL] [Abstract][Full Text] [Related]
17. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia. Steinberg M Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072 [TBL] [Abstract][Full Text] [Related]
18. The impacts of BCR-ABL1 mutations in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia who underwent allogeneic hematopoietic cell transplantation. Tachibana T; Najima Y; Akahoshi Y; Hirabayashi S; Harada K; Doki N; Uchida N; Fukuda T; Sawa M; Ogata M; Takada S; Tanaka M; Matsuhashi Y; Tanaka J; Onizuka M; Ichinohe T; Atsuta Y; Kako S; Ann Hematol; 2020 Oct; 99(10):2393-2404. PubMed ID: 32803312 [TBL] [Abstract][Full Text] [Related]
19. BCR/ABL1-like acute lymphoblastic leukemia: How to diagnose and treat? Chiaretti S; Messina M; Foà R Cancer; 2019 Jan; 125(2):194-204. PubMed ID: 30561755 [TBL] [Abstract][Full Text] [Related]
20. Philadelphia Chromosome Positive and Philadelphia-Like Acute Lymphoblastic Leukemia in Children and Adolescents: Current Management, Controversies and Emerging Concepts. Ganguly S; Sasi A; Pushpam D; Bakhshi S Indian J Pediatr; 2024 Jan; 91(1):37-46. PubMed ID: 37632689 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]